About this trial
This clinical trial studies if a bowel management program with a retrograde rectal enema (RRE) for the treatment of low anterior resection syndrome (LARS) in rectal cancer patients is better than medical management alone. Rectal cancer treatment can include a procedure where part of the rectum with cancer is removed and the remaining part of the rectum is reconnected to the colon, this is called a low anterior resection of the rectum. LARS is a common condition that can develop after undergoing a low anterior resection of the rectum. LARS consists of any change in how the body performs defecation, the discharge of feces from the body, after undergoing a resection procedure. Patients with LARS may experience fecal urgency, incontinence, increased frequency, constipation, feelings of incomplete bowel movement, or bowel emptying difficulties. Patients may experience individual symptoms of LARS or a combination of them. A bowel management program assists patient's with identifying a specific bowel management regimen that works best for managing symptoms of LARS. A RRE consists of inserting a catheter through the anus into the rectum. The RRE is designed to assist fecal emptying. Medical management of LARS can include the use of fiber, loperamide hydrochloride, or pelvic floor physical therapy. Fiber may help relieve constipation, feelings of incomplete bowel movement, or bowel emptying difficulties. Loperamide hydrocholoride may help lessen fecal urgency, incontinence, or increased frequency. Pelvic floor physical therapy may help restore strength in the rectum possibly helping to improve symptoms of LARS. Participating in a bowel management program with a RRE may be more effective in treating LARS than medical management alone.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years old
Moderate to Severe LARS diagnosis
Patients with history of rectal cancer that was treated with proctectomy
Has undergone standard medical management without improvement of symptoms for 3-6 months
Disqualifiers
Patients presenting with significant stricture that need a definitive surgical management strategy; patients with minor or clinically negligible strictures can still be candidates. Patients who are able to pass the catheter and the balloon per rectum may be candidates after a digital rectal exam at their initial visit
Patients with any chemo or radiation therapy in the last 6 months
Patients who currently have colorectal cancer
Patients with recurrent colorectal cancer
Trial design
Parallel
Treatments tested in this trial
Dietary Fiber
Dietary supplementReceive dietary fiber
Enema Administration
Procedure/SurgeryUndergo RRE
Loperamide Hydrochloride
DrugReceive loperamide hydrochloride
Physical Therapy
Procedure/SurgeryUndergo pelvic floor physical therapy
Questionnaire Administration
Other interventionAncillary studies
X-Ray Imaging
Procedure/SurgeryUndergo abdominal film x-ray
Treatment groups
Trial outcomes
Primary outcomes
Fecal incontinence
Will be measured using a validated scoring tool for LARS (Memorial Sloan Kettering Cancer Center Bowel Function Instrument Questionnaire \[MSKCC BFI\]). Effect size (Cohen's d \> 0.80) will be computed to ensure the effect of findings. P \< 0.05 is considered significant. Statistical analysis will be conducted using linear or nonlinear mixed modelling as found appropriate by the statistician.
Effectiveness assessed using LARS validated scoring tool
Will be assessed using LARS validated scoring tool. Effect size (Cohen's d \> 0.80) will be computed to ensure the effect of findings. P \< 0.05 is considered significant. Statistical analysis will be conducted using linear or nonlinear mixed modelling as found appropriate by the statistician.
Secondary outcomes
Feasibility measured by Patient Satisfaction Survey
Will be assessed by administering a patient satisfaction survey post treatment. Effect size (Cohen's d \> 0.80) will be computed to ensure the effect of findings. P \< 0.05 is considered significant. Statistical analysis will be conducted using linear or nonlinear mixed modelling as found appropriate by the statistician.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.